Centene (CNC) Gets a Buy from J.P. Morgan

In a report released today, Lisa Gill from J.P. Morgan maintained a Buy rating on Centene (CNCResearch Report), with a price target of $98.00. The company’s shares opened today at $77.75.

According to TipRanks, Gill is a 5-star analyst with an average return of 14.2% and a 59.02% success rate. Gill covers the Healthcare sector, focusing on stocks such as Teladoc, Cardinal Health, and Centene.

Currently, the analyst consensus on Centene is a Moderate Buy with an average price target of $97.67.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $98.53 and a one-year low of $73.20. Currently, Centene has an average volume of 3.6M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Centene Corporation is a diversified healthcare company that primarily engages in providing programs and services to the government sponsored healthcare programs. The company is also engaged in providing education and outreach programs to assist members in accessing quality and appropriate healthcare services.

Read More on CNC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More